Comparative Pharmacology
Head-to-head clinical analysis: QTERN versus ZITUVIMET XR.
Peer-Reviewed Evidence
Head-to-head clinical analysis: QTERN versus ZITUVIMET XR.
QTERN vs ZITUVIMET XR
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
QTERN is a fixed-dose combination of dapagliflozin, a sodium-glucose cotransporter 2 (SGLT2) inhibitor, and saxagliptin, a dipeptidyl peptidase-4 (DPP-4) inhibitor. Dapagliflozin reduces renal glucose reabsorption, increasing urinary glucose excretion. Saxagliptin increases incretin hormones, enhancing insulin secretion and decreasing glucagon levels.
Zituvimet XR (sitagliptin/metformin) is a combination of a dipeptidyl peptidase-4 (DPP-4) inhibitor (sitagliptin) and a biguanide (metformin). Sitagliptin increases incretin levels (GLP-1, GIP), enhancing insulin secretion and decreasing glucagon secretion. Metformin decreases hepatic glucose production, decreases intestinal absorption of glucose, and improves insulin sensitivity by increasing peripheral glucose uptake and utilization.
One tablet orally twice daily; each tablet contains dapagliflozin 10 mg and saxagliptin 5 mg.
Initial: 1000 mg (2 tablets) orally once daily with the evening meal. Titrate based on efficacy and tolerability. Maximum daily dose: 2000 mg (4 tablets).
None Documented
None Documented
Terminal half-life approximately 5 hours; supports twice-daily dosing.
Sitagliptin: 12.4 h (prolonged in renal impairment); metformin: 6.2 h (prolonged in renal impairment). Clinically, twice-daily dosing for immediate-release, but ZITUVIMET XR is once-daily.
Fecal (59% unchanged) and renal (42% unchanged, primarily via tubular secretion).
Renal: sitagliptin ~79% unchanged in urine; metformin ~90% unchanged in urine via tubular secretion. Biliary/fecal: minimal.
Category C
Category C
Antidiabetic Combination
Antidiabetic Combination